Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
About this item
Full title
Author / Creator
Jhaveri, Chirag D. , Glassman, Adam R. , Ferris, Frederick L. , Liu, Danni , Maguire, Maureen G. , Allen, John B. , Baker, Carl W. , Browning, David , Cunningham, Matthew A. , Friedman, Scott M. , Jampol, Lee M. , Marcus, Dennis M. , Martin, Daniel F. , Preston, Carin M. , Stockdale, Cynthia R. and Sun, Jennifer K.
Publisher
Boston: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Some insurance companies mandate a form of step therapy, which involves initial use of an inexpensive drug, bevacizumab, to treat diabetic macular edema. This trial compared two treatments: step therapy and use of a more expensive drug.
Alternative Titles
Full title
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2706435872
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2706435872
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2204225
